Epigallocatechin-3-gallate modulates antioxidant and DNA repair-related proteins in exocrine glands of a primary Sjogren's syndrome mouse model prior to disease onset

Autoimmunity

Volumn 45, Issue 7, 2012, Pages 540-546

  Ohno, Seiji ^a   Yu, Hongfang ^b   Dickinson, Douglas ^b   Chu, Tin Chun ^c   Ogbureke, Kalu ^b   Derossi, Scott ^b   Yamamoto, Tetsuya ^a   Hsu, Stephen ^b  

^a KOCHI MEDICAL SCHOOL   (Japan)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c SETON HALL UNIVERSITY   (United States)

Author keywords

EGCG; NOD; PCNA; Salivary gland; Sjogren's syndrome

Indexed keywords

CATALASE; CYCLINE; EPIGALLOCATECHIN GALLATE; PEROXIREDOXIN 6; SUPEROXIDE DISMUTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DNA REPAIR; DRUG EFFECT; EXOCRINE GLAND; FEMALE; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PANCREAS; PROTEIN EXPRESSION; SJOEGREN SYNDROME; SUBMANDIBULAR GLAND;

ANIMALS; ANTIBODIES, ANTINUCLEAR; ANTIOXIDANTS; CATECHIN; DISEASE MODELS, ANIMAL; DNA REPAIR; EXOCRINE GLANDS; FEMALE; LYMPHOCYTES; MICE; MICE, INBRED NOD; PEROXIREDOXIN VI; PROLIFERATING CELL NUCLEAR ANTIGEN; SJOGREN'S SYNDROME; TIME FACTORS;

EID: 84867075845     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2012.710860     Document Type: Article

References (45)

1. Bolstad AI, Jonsson R. Genetic aspects of Sjögren's syndrome. Arthritis Res. 2002;4:353-359.
2. Yamamoto K. Pathogenesis of Sjögren's syndrome. Autoimmun. Rev. 2003;2:13-18.
3. Sawalha AH, Potts R, Schmid WR, Scofield RH, Harley JB. The genetics of primary Sjögren's syndrome. Curr. Rheumatol. Rep. 2003;5:324-332.
4. Rehman HU. Sjögren's syndrome. Yonsei Med. J. 2003;44: 947-954.
5. Mahoney EJ, Spiegel JH. Sjögren's disease. Otolaryngol. Clin. N. Amer. 2003;36:733-745.
6. Venables PJ. Sjögren's syndrome. Best Pract. Res. Clin. Rheumatol. 2004;18:313-329.
7. Manganelli P, Fietta P. Apoptosis and Sjögren's syndrome. Semin. Arthritis Rheum. 2003;33:49-65.
8. Hayashi Y, Arakaki R, Ishimaru N. The role of caspase cascade on the development of primary Sjögren's syndrome. J. Med. Invest. 2003;50:32-38.
9. Hayashi Y, Arakaki R, Ishimaru N. Apoptosis and estrogen deficiency in primary Sjögren's syndrome. Curr. Opin. Rheumatol. 2004;16:522-526.
10. Burbelo PD, Leahy HP, Issa AT, Groot S, Baraniuk JN, Nikolov NP, Illei GG, Iadarola MJ. Sensitive and robust luminescent profiling of anti-La and other autoantibodies in Sjogren's syndrome. Autoimmunity 2009;42:515-524.
11. Cravens PD, Lipsky PE. Dendritic cells, chemokine receptors and autoimmune inflammatory diseases. Immunol. Cell. Biol. 2002;80:497-505.
12. van Woerkom JM, Geertzema JG, Nikkels PG, Kruize AA, Smeenk RJ, Vroom TM. Expression of Ro/SS-A and La/SS-B determined by immunohistochemistry in healthy, inflamed and autoimmune diseased human tissues: a generalized phenomenon. Clin. Exp. Rheumatol. 2004;22:285-292.
13. Thompson C, Pomeranz Krummel DA, Jacobsen H, Nagai K, Cooke A. Identification of nuclear spliceosomal antigens targeted by NOD mouse antibodies following sodium iodide intake. Autoimmunity 2006;39:99-106.
14. Gillespie K, Kodani I, Dickinson DP, Ogbureke KUE, Camba AM, Wu M, Looney S, Chu TC, Qin H, Bisch F, Sharawy M, Schuster GS, Hsu SD. Effects of oral consumption of the green tea polyphenol EGCG in a murine model for human Sjogren's syndrome, an autoimmune disease. Life Sci. 2008;83:581-588.
15. Mukhtar H, Ahmad N. Tea polyphenols: prevention of cancer and optimizing health. Am. J. Clin. Nutr. 2000;71(6 Suppl): 1698S-1702S, discussion 1703S-1704S.
16. Yang CS, Maliakal P, Meng X. Inhibition of carcinogenesis by tea. Annu. Rev. Pharmacol. Toxicol. 2002;42:25-54.
17. Katiyar SK, Elmets CA. Green tea polyphenolic antioxidants and skin photoprotection (Review). Int. J. Oncol. 2001;18: 1307-1313.
18. Sueoka N, Suganuma M, Sueoka E, Okabe S, Matsuyama S, Imai K, Nakachi K, Fujiki H. A new function of green tea: Prevention of lifestyle-related diseases. Ann. N.Y. Acad. Sci. 2001;928:274-280.
19. Green tea. Altern. Med. Rev. 2000;5:372-375.
20. Hsu S, Dickinson D. Green Tea: A new approach to managing oral manifestations of Sjogren's Syndrome and skin manifestations of lupus. J. Biochem. Molec. Biol. 2006;39:229-239, Review.
21. Hsu S, Dickinson DP, Qin H, Borke J, Ogbureke K, Winger JN, Walsh DS, Bollag WB, Stoppler H, Sharawy M, Schuster G. Green tea polyphenols reduce autoimmune symptoms in a murine model for human Sjogren's syndrome and protect human salivary acinar cells from TNFalpha- induced cytotoxicity. Autoimmunity 2007;40:138-147.
22. Cha S, Peck AB, Humphreys-Beher MG. Progress in understanding autoimmune exocrinopathy using the nonobese diabetic mouse: An update. Crit. Rev. Oral Biol. Med. 2002;13:4-16.
23. Frei B, Higdon JV. Antioxidant activity of tea polyphenols in vivo: Evidence from animal studies. J. Nutr. 2003;133: 3275S-3284S.
24. Yang CS, Lee MJ, Chen L. Human salivary tea catechin levels and catechin esterase activities: implication in human cancer prevention studies. Cancer Epidemiol. Biomarkers Prev. 1999; 8:83-89.
25. Yamamoto T, Hsu S, Lewis J,Wataha J, DickinsonD, Singh B, Bollag WB, Lockwood P, Ueta E, Osaki TT, Schuster G. Green tea polyphenol causes differential oxidative environments in tumor versus normal epithelial cells. J. Pharmacol. Exp. Ther. 2003;307:230-236.
26. Yamamoto T, Staples J, Wataha J, Lewis J, Lockwood P, Schoenlein P, Rao S, Osaki T, Dickinson D, Kamatani T, Schuster G, Hsu S. Protective effects of EGCG on salivary gland cells treated with gamma-radiation or cis-platinum(II)- diammine dichloride. Anticancer Res. 2004;24:3065-3073.
27. Yang F, de Villiers WJ, McClain CJ, Varilek GW. Green tea polyphenols block endotoxin-induced tumor necrosis factorproduction and lethality in a murine model. J. Nutr. 1998;128: 2334-2340.
28. Power JH, Asad S, Chataway TK, Chegini F, Manavis J, Temlett JA, Jensen PH, Blumbergs PC, GaiWP. Peroxiredoxin 6 in human brain: molecular forms, cellular distribution and association with Alzheimer's disease pathology. Acta Neuropathol. 2008;115:611-622.
29. Kümin A, Schäfer M, Epp N, Bugnon P, Born-Berclaz C, Oxenius A, Klippel A, Bloch W, Werner S. Peroxiredoxin 6 is required for blood vessel integrity in wounded skin. J. Cell Biol. 2007;179:747-760.
30. Kümin A, Huber C, Rü licke T, Wolf E, Werner S. Peroxiredoxin 6 is a potent cytoprotective enzyme in the epidermis. Am. J. Pathol. 2006;169:1194-1205.
31. Fatma N, Kubo E, Sen M, Agarwal N, Thoreson WB, Camras CB, Singh DP. Peroxiredoxin 6 delivery attenuates TNF-alpha-and glutamate-induced retinal ganglion cell death by limiting ROS levels and maintaining Ca(2 + ) homeostasis. Brain Res. 2008;1233:63-78.
32. Wang Y, Feinstein SI, Fisher AB. Peroxiredoxin 6 as an antioxidant enzyme: protection of lung alveolar epithelial type II cells from H2O2-induced oxidative stress. J. Cell Biochem. 2008;104:1274-1285.
33. Kubo E, Fatma N, Akagi Y, Beier DR, Singh SP, Singh DP. TAT-mediated PRDX6 protein transduction protects against eye lens epithelial cell death and delays lens opacity. Am. J. Physiol. Cell Physiol. 2008;294:C842-C855.
34. Zhang G,Wang S. Proteomic approach to substrates related to MAPK pathway in 293T cells. Cell Biol. Int. 2007;31:1-10.
35. Daniels TE. Salivary histopathology in diagnosis of Sjogren's Syndrome. Scand. J. Rheumatol. 1986;61:36-43.
36. Greenspan JS, Daniels TE, Talal N, Sylvester RA. The histopathology Sjogren's syndrome in labial salivary gland biopsies. Oral Surg. 1974;37:217-229.
37. Lavasani S, Henriksson G, Brant M, Henriksson A, Radulic M, Manthorpe R, Bredberg A. Abnormal DNA damage-inducible protein in cells from Sjö gren's syndrome patients. J. Autoimmun. 1998;11:363-369.
38. Kurimoto C, Kawano S, Tsuji G, Hatachi S, Jikimoto T, Sugiyama D, Kasagi S, Komori T, Nakamura H, Yodoi J, Kumagai S. Thioredoxin may exert a protective effect against tissue damage caused by oxidative stress in salivary glands of patients with Sjögren's syndrome. J. Rheumatol. 2007;34: 2035-2043.
39. Hübscher U, Maga G. DNA replication and repair bypass machines. Curr. Opin. Chem. Biol. 2011;15:627-635.
40. Kirchmaier AL. Ub-family modifications at the replication fork: Regulating PCNA-interacting components. FEBS Lett. 2011;585:2920-2928.
41. Celenligil-Nazliel H, Palali A Ahyan, Ruacan S. Analysis of in situ proliferative activity in oral gingival epithelium in patients with xerostomia. J. Periodont. 2003;74:247-254.
42. Perl A. Emerging new pathways of pathogenesis and targets for treatment in systemic lupus erythematosus and Sjogren's syndrome. Curr. Opin. Rheumatol. 2009;21:443-447.
43. Kim SY, Chun E, Lee KY. Phospholipase A(2) of peroxiredoxin 6 has a critical role in tumor necrosis factorinduced apoptosis. Cell Death Differ. 2011;18:1573-1583.
44. EismannT, Huber N, ShinT,Kuboki S, Galloway E,WyderM, Edwards MJ, Greis KD, Shertzer HG, Fisher AB, Lentsch AB. Peroxiredoxin-6 protects against mitochondrial dysfunction and liver injury during ischemia-reperfusion in mice. Am J Physiol Gastrointest Liver Physiol 2009;296:G266-G274.
45. Newsholme P, Haber EP, Hirabara SM, Rebelato EL, Procopio J, Morgan D, Oliveira-Emilio HC, Carpinelli AR, Curi R. Diabetes associated cell stress and dysfunction: role of mitochondrial and non-mitochondrial ROS production and activity. J. Physiol. 2007;583:9-24.